Kite: FDA Approves Label Update For Yescarta

February 06, 2026 — 08:55 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Kite, a Gilead Company (GILD), announced the FDA approved an update to the Yescarta prescribing information removing the previous Limitations of Use in patients with relapsed or refractory primary central nervous system lymphoma. The FDA decision is based on positive results from a Phase 1 investigator-sponsored study.

Gallia Levy, Senior Vice President and Global Head of Development, Kite, said: "We appreciate the FDA's timely review and decision, which expands access to Yescarta for patients with primary central nervous system lymphoma-one of the most aggressive and underserved forms of the disease-and we are deeply grateful to the patients and clinicians who made this progress possible."

In pre-market trading on NasdaqGS, Gilead shares are up 0.35 percent to $149.90.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Kite: FDA Approves Label Update For Yescarta

Tags

Latest Articles